Keyphrases
Peru
100%
Virological Failure
100%
HIV Drug Resistance
100%
First-line Antiretroviral Therapy
100%
Pretreatment HIV Drug Resistance
100%
Antiretroviral Therapy
50%
Oligonucleotide Ligation Assay
40%
Antiretroviral Naïve
40%
Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)
30%
Peruvian
20%
Codon
20%
Drug Resistance
10%
Nucleoside Reverse Transcriptase Inhibitors
10%
M184V
10%
Blood Specimen
10%
K65R
10%
Transmitted Resistance
10%
Reverse Transcriptase
10%
Therapeutic Program
10%
HIV Quasispecies
10%
K103N
10%
Sanger
10%
Low-level Resistance
10%
Y181C
10%
HIV Viral Load
10%
Increasing Prevalence
10%
Medicine and Dentistry
Antiretroviral Therapy
100%
HIV Drug Resistance
100%
Oligonucleotide
36%
Ligation
36%
Human Immunodeficiency Virus
27%
Nonnucleoside Reverse Transcriptase Inhibitor
27%
Prevalence
18%
Codon
18%
Drug Resistance
9%
Reverse-Transcriptase Inhibitor
9%
Resistance Mutation
9%
RNA Directed DNA Polymerase
9%
Quasispecies
9%
Neuroscience
Human Immunodeficiency Virus
100%
Drug Resistance
100%
Oligonucleotide
28%
Non-Nucleoside Reverse Transcriptase Inhibitors
21%
Codon
14%
Reverse Transcriptase
7%
Reverse-Transcriptase Inhibitor
7%
Blood Plasma
7%
Immunology and Microbiology
Human Immunodeficiency Virus
100%
Drug Resistance
100%
Reverse Transcriptase
35%
Prevalence
14%
Codon
14%
Blood Plasma
7%
Quasispecies
7%
Pharmacology, Toxicology and Pharmaceutical Science
HIV Drug Resistance
100%
Oligonucleotide
36%
HIV
27%
Nonnucleoside Reverse Transcriptase Inhibitor
27%
Prevalence
18%
RNA Directed DNA Polymerase
9%
Drug Resistance
9%
RNA Directed DNA Polymerase Inhibitor
9%